The Daily

Reuters reports that a U.S. advisory body is warning Washington that China’s increasing dominance in open-source AI models could translate into real strategic advantage — not because open source is “free,” but because it sets the default tooling for developers worldwide. The concern is simple: if the global ecosystem standardizes on Chinese-led stacks, the U.S. loses leverage even if it still leads on frontier training runs. The report lands while export controls and compute access are tightening — which can unintentionally push more innovation into open implementations. The implication for companies: procurement and security teams will have to treat “model provenance” like they already treat supply chains. And for policymakers: you can’t regulate your way out of an ecosystem war.

Alibaba is pushing harder into the “AI agents” category with Accio Work, launched via its international unit, according to Reuters. The bet is that companies don’t want a single chatbot — they want workflows that can plan, execute, and hand off tasks across internal systems. The near-term tell will be integration: whether Accio Work can plug into the boring enterprise stack (docs, tickets, CRMs) with audit trails and permissions. If it can, it competes less with consumer AI and more with enterprise platforms that are trying to become AI-native by default.

Reuters (citing the Financial Times) says OpenAI plans to grow from 4,500 to 8,000 employees by the end of 2026 — with most hires going into product, engineering, research and sales. A notable detail: recruitment of “technical ambassadorship” roles to help enterprises actually use the tools, not just buy them. It’s a reminder that the bottleneck isn’t only GPUs and models; it’s adoption inside messy organizations. This kind of hiring wave also signals that the enterprise land-grab is turning into a services-and-deployment race, not a pure model-quality contest.

TechCrunch profiles Gimlet Labs, a startup aiming at the least glamorous but most expensive part of modern AI: inference. The pitch is efficiency — making models cheaper to run at scale without asking customers to rebuild everything from scratch. If that works, it matters more than another flashy demo: inference cost is what turns “cool model” into “budget line item.” The implication is competitive pressure on cloud providers and model vendors alike, because the winner isn’t always the best model — it’s the stack that delivers the best $/latency for real traffic.

Kurzliste: Malma Art Café (1050) · Papa Duck (1060) · Krawall Bar & Deli (1070) · HUHU Hotpot (1030) · Partenope (1060). Goodnight sammelt die März-Neueröffnungen als brauchbare „was ist neu?“-Karte für die nächsten zwei Wochen. Spannend ist weniger das Trendwort-Bingo als die Bandbreite: Art-Café mit Workshops, Urban-Asian mit Inari-Taschen, eine Bar, die oben Deli ist und unten Club, plus All-you-can-eat Hotpot und ein bewusst kleines Fischlokal (ca. 40 Sitzplätze). Für die Planung taugen vor allem die harten Details: Adressen, Bezirke, Öffnungsfenster (z.B. Mo–Fr 12:00–14:00 Mittagsmenüs bei HUHU) und ein paar Signature-Hinweise.

Die Albertina plant ihr Jubiläumsjahr mit drei großen Sammlungsschauen — und holt dafür auch den „Feldhasen“ (1502) von Albrecht Dürer wieder „aus dem Stall“, schreibt wien.ORF.at. Terminanker: 19. Juni („Sammeln für die Zukunft“) und 30. Oktober („Künstlerinnen der Albertina“), dazu ein zweitägiges Geburtstagsfest am 4./5. Juli bei freiem Eintritt. Der Punkt dahinter: 2026 wird in Wien wieder ein Jahr, in dem die großen Häuser nicht nur Blockbuster einkaufen, sondern ihre eigenen Bestände neu erzählen. Wer Besuche plant, kann sich jetzt schon den Sommer/Herbst kalibrieren.

Patients with leptomeningeal metastasis have historically had vanishingly few options — so even small datasets matter. The ASCO Post summarizes results from the phase II TBCRC049 study (n=17), where the triplet of tucatinib, trastuzumab and capecitabine lifted median overall survival to 10 months versus a historical 4.4 months. At 18 months, 41% of patients were still alive, and median time to CNS progression was 7 months. Dosing detail: 21-day cycles with tucatinib 300 mg BID, capecitabine 1,000 mg/m² BID on days 1–14, and IV trastuzumab 6 mg/kg on day 21. It’s not definitive, but it’s a credible “this regimen actually reaches where it needs to” data point.

A new paper in J Nanobiotechnology (PMID 41845388, online ahead of print; doi:10.1186/s12951-026-04242-3) engineers iPSC-derived exosomes as a bispecific bridge (PD‑1 / mesothelin) and drug carrier to boost CAR‑T in solid tumors. The authors report that their nebulized platform achieved 79.3% tumor-cell uptake (vs 47.9% for liposomes) and cut tumor burden by 87.9% in an orthotopic lung cancer model, with 80% survival at 80 days. In combination with CAR‑T, they report 66.7% complete remission and 100% survival at 80 days, plus 83.3% resistance to tumor rechallenge. It’s preclinical — but the hard question it tackles is real: delivery + exhaustion in solid tumors, not “does CAR‑T kill cells in a dish.”

Sanofi is back in the T-cell engager game — this time in autoimmunity. Fierce Biotech reports a deal with Kali Therapeutics for KT501, a trispecific antibody designed to bind CD3, CD19 and BCMA, already in a phase 1 first-in-human rheumatoid arthritis study (NCT07234773). The economics: $180M upfront/near-term, plus up to $1.05B in milestones and tiered royalties (headline: $1.2B). The big implication is strategic: after selling off earlier TCE assets, Sanofi is signaling that “deep B-cell depletion, but safer cytokine profile” is still worth paying for. If KT501’s cytokine-release minimization holds up clinically, it’s a platform bet — not a single-asset punt.

uniQure confirmed the FDA rejected its plan to file based on phase 1/2 data plus an external control for AMT-130 in Huntington’s disease, triggering a >40% premarket share drop, Fierce reports. The agency recommended a prospective, randomized, double-blind, sham surgery-controlled study — effectively a phase 3 demand. uniQure argues a one-year sham window is too short to detect progression in early Huntington’s, and that multi-year sham surgery controls raise feasibility and ethical concerns. A concrete next step: the company plans to update its phase 1/2 statistical analysis plan to add a four-year analysis expected in Q3. The broader signal is uncomfortable: the FDA bar for rare-disease gene therapies appears to be rising even as “regulatory flexibility” is publicly emphasized.

EndoCyclic Therapeutics announced FDA clearance of its IND for ENDO-205, positioned as a first-in-class, non-hormonal “precision peptide” therapeutic for endometriosis. The strategic angle is that endometriosis remains a market where symptom management is often hormonal and long-term, while many patients want options that don’t trade pain relief for systemic side effects. What to watch next is the trial design: endpoints (pain, lesion burden, quality-of-life), duration, and how fast the program can recruit. If ENDO-205 can show meaningful efficacy without the usual hormonal baggage, it’s the kind of profile that can change prescribing behavior quickly.

The Art Newspaper reports that Venice mayor Luigi Brugnaro said the Russian pavilion at the Venice Biennale would be shut down if it engages in propaganda (comments reported by Italian media including ANSA). The trigger is Russia’s announced participation (first since the full-scale invasion of Ukraine in February 2022), with a musical program. A concrete detail in the background: the Biennale’s Central Pavilion reopened after a 16-month, €31m renovation — so the politics are colliding with a moment of institutional showcase. For travelers, the useful framing is: this year’s Biennale won’t be “just art tourism”; it will come with real protest/counter-programming dynamics. If you’re going, plan for context — and for headlines.

Wanted in Rome notes that Italy was the most represented country in the European Best Destinations 2026 Top 20 list, with seven spots included. The ranking is based on votes from 1.3 million travelers across 154 countries, and explicitly weights heritage, sustainability, and “authentic experiences.” Rankings are rankings — but they do influence where second-tier destinations suddenly get a spike in bookings and Instagram gravity. Practical takeaway: if you want Italy with less crowd pressure, tracking these lists early can help you book before the algorithm does.

NBA.com’s nightly recap frames Sunday as a “small slate, big signals” kind of night. The headline is Minnesota: the Timberwolves got their first win in Boston since 2005, with Karl-Anthony Towns highlighted as Player of the Night. New York also stayed hot with a sixth straight win, while Phoenix ended a losing skid. These are late-season games that matter less for aesthetics and more for seeding psychology: can a team win ugly, on the road, in a hostile building? Minnesota answered that question in the cleanest possible way.

Fox Sports reports that Moses Moody had to be carted off after an apparent knee injury late in overtime against Dallas — the kind of moment that instantly changes a team’s rotation math. At this point of the season, even “not-a-superstar” injuries can swing playoff matchups because bench wings are exactly who you need to survive shortened rotations. The near-term watch is MRI/return timeline and whether Golden State has to reshuffle defensive assignments. It’s a reminder that, in the NBA, availability is still the most brutal advanced stat.

Kurzliste: „Salat“ (6 Monate–2 Jahre) · „Eltern Kind Bass“ (3–8 Jahre) · Kalvarienbergfest (Ostermarkt, 18 Tage) · „Vom T‑Shirt zur Tasche“ (7–12 Jahre) · VinziRast-Ostermarkt (mit Osterbastelei). Falter bündelt hier die wöchentlich aktualisierten Kinderkultur-Tipps, und das Format ist genau richtig: kurze Beschreibungen, klare Altersfenster, und genug Kontext, um schnell zu entscheiden. Besonders praktisch sind die Angebote, die nicht nur „anschauen“, sondern „mitmachen“ erlauben — Workshop statt reiner Bühne. Wer mit mehreren Kindern unterwegs ist, kann so einen Plan bauen, der nicht nach 30 Minuten kippt.

Kurzliste: Kuscheltier-Werkstatt (27.–29.3. & 3.–5.4.) · Oster-Entdecker-Mission (5 Verstecke, kleine Überraschung) · Sonderöffnungszeiten (27.3.–5.4., meist 10:00–19:00). Mamilade listet das Osterferien-Programm der Playworld Wien inklusive Preisanker: ein Kuscheltier-Set kostet €29,90, Kleidung pro Teil €12. Für Familien ist vor allem die Planbarkeit hilfreich: klare Zeitfenster (z.B. Fr 27.03. 14:00–18:00) und ein Mix aus „freies Spielen“ plus Mini-Event. Das ist kein Kulturprogramm — aber es ist genau die Art von Indoor-Backup, die man in März/April wirklich braucht.